KASID
Search
- Page Path
- HOME > Search
Original Articles
- IBD
- Risk of malignancies and chemopreventive effect of statin, metformin, and aspirin in Korean patients with ulcerative colitis: a nationwide population-based study
- Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
- Intest Res 2025;23(2):129-143. Published online November 9, 2023
- DOI: https://doi.org/10.5217/ir.2023.00062
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Background/Aims
We investigated the incidences of overall and site-specific malignancies and chemopreventive effects of statin, metformin, and aspirin in patients with ulcerative colitis.
Methods
We collected data using the Health Insurance Review and Assessment claims database from January 2007 to April 2020.
Results
The overall malignancy risk among the 35,189 ulcerative colitis patients was similar to that of the general population (standardized incidence ratio, 0.94; 95% confidence interval, 0.88–1.00). In male patients, standardized incidence ratios were high for thyroid cancer and low for stomach cancer, colorectal cancer, liver cancer, and lung cancer. Concurrently, standard incidence ratios were high for liver cancer and central nervous system cancer in female patients. While 122 cases of colorectal cancer occurred in the study patients, the standardized incidence ratio was 0.83 (95% confidence interval, 0.69–0.99). Treatment for ulcerative colitis was not associated with an increased adjusted hazard ratio, while comorbidities increased it for all malignancies. Treatment for ulcerative colitis was associated with an increased adjusted hazard ratio, while comorbidities did not increase it for colorectal cancer. After adjusting for age, sex, comorbidities, and ulcerative colitis treatment, statins showed a dose-dependent chemopreventive effect for all malignancies (P=0.002), while metformin and aspirin did not show any.
Conclusions
In ulcerative colitis patients, standardized incidence ratios for all malignancies and colorectal cancer did not increase. Adjusted hazard ratios for all malignancies increased with comorbidities and those for colorectal cancer with ulcerative colitis treatment. Statins have a dose-dependent chemopreventive effect for all malignancies. -
Citations
Citations to this article as recorded by
- Thyroid disorders and inflammatory bowel disease: an association present in adults but also in children and adolescents
Valeria Calcaterra, Francesca Penagini, Virginia Rossi, Luisa Abbattista, Alice Bianchi, Massimiliano Turzi, Lucia Cococcioni, Gianvincenzo Zuccotti
Frontiers in Endocrinology.2025;[Epub] CrossRef - Does statin have a chemopreventive effect in patients with ulcerative colitis?
Yoon Suk Jung
Intestinal Research.2025; 23(2): 113. CrossRef
- Thyroid disorders and inflammatory bowel disease: an association present in adults but also in children and adolescents
- 3,372 View
- 445 Download
- 2 Web of Science
- 2 Crossref
- IBD
- Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study
- Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
- Intest Res 2023;21(2):252-265. Published online December 2, 2022
- DOI: https://doi.org/10.5217/ir.2022.00092
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
We conducted a nationwide population-based study to investigate incidence rates of colorectal and biliary cancers according to accompanying primary sclerosing cholangitis in Korean ulcerative colitis patients.
Methods
We used the Health Insurance Review and Assessment claim database from January 2007 to April 2020. Standardized incidence ratios of colorectal and biliary cancers in ulcerative colitis patients were calculated.
Results
Among 35,189 newly diagnosed ulcerative colitis patients, 1,224 patients were diagnosed with primary sclerosing cholangitis. During the study period, 122 and 52 patients were diagnosed with colorectal and biliary cancers, respectively. Incidences of colorectal cancer were not higher in ulcerative colitis patients than those in the general population (standardized incidence ratios, 0.83; 95% confidence interval, 0.69–0.99), regardless of accompanied primary sclerosing cholangitis (standardized incidence ratio, 0.73; 95% confidence interval, 0.24–1.71). While incidences of biliary cancer were not higher in ulcerative colitis patients than those in the general population (standardized incidence ratio, 1.14; 95% confidence interval, 0.80–1.58), these were much higher with accompanied primary sclerosing cholangitis (standardized incidence ratio, 10.07; 95% confidence interval, 5.75–16.36). Cumulative incidences of colorectal and biliary cancers increased in patients who were diagnosed with ulcerative colitis at an older age.
Conclusions
In Korean ulcerative colitis patients, colorectal cancer incidences were not higher than those in the general population regardless of accompanied primary sclerosing cholangitis. However, biliary cancer incidences were much higher in ulcerative colitis patients with primary sclerosing cholangitis than in those without, or in the general population. -
Citations
Citations to this article as recorded by- Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
Intestinal Research.2023; 21(4): 420. CrossRef - Are the risks of colorectal cancer and biliary cancer really increased if patients with ulcerative colitis have primary sclerosing cholangitis?
Jung Wook Lee, Won Moon
Intestinal Research.2023; 21(2): 171. CrossRef
- Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
- 4,043 View
- 338 Download
- 3 Web of Science
- 2 Crossref
- IBD
- Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
- Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Do Hyun Kim, Dennis Teng, Jong-Hwa Kim, Wonyong Kim, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
- Intest Res 2022;20(3):350-360. Published online July 23, 2021
- DOI: https://doi.org/10.5217/ir.2021.00049
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC).
Methods
A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score.
Results
A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients.
Conclusions
ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response. -
Citations
Citations to this article as recorded by- Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study
Sivan Harnik, Chaya M Abitbol, Ola Haj Natour, Miri Yavzori, Ella Fudim, Orit Picard, Timna Naftali, Efrat Broide, Ayal Hirsch, Limor Selinger, Eyal Shachar, Doron Yablecovitch, Ahmad Albshesh, Daniel Coscas, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin,
Journal of Crohn's and Colitis.2024; 18(3): 341. CrossRef - Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes
Rirong Chen, Yizhe Tie, Yongle Huang, Xi Zhang, Zhirong Zeng, Minhu Chen, Li Li, Shenghong Zhang
United European Gastroenterology Journal.2024; 12(4): 459. CrossRef - Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
Saleh Azadbakht, Masomeh Seighali, Salehe Azadbakht, Morteza Azadbakht
Health Science Reports.2024;[Epub] CrossRef - Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
Gut Pathogens.2024;[Epub] CrossRef - Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
Peter M. Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire
Journal of Managed Care & Specialty Pharmacy.2024; 30(9): 1026. CrossRef - Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
Intestinal Research.2023; 21(1): 61. CrossRef - Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
Seok-Young Kim, Seung Yong Shin, Soo Jung Park, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef - Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
Intestinal Research.2023; 21(2): 174. CrossRef - Precision medicine and drug optimization in adult inflammatory bowel disease patients
Sophie Vieujean, Edouard Louis
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef - Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
The Korean Journal of Internal Medicine.2023; 38(5): 661. CrossRef - Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
Soo-Young Na
The Korean Journal of Medicine.2023; 98(5): 223. CrossRef - Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms
Seok-Young Kim, Seung Yong Shin, Maham Saeed, Ji Eun Ryu, Jung-Seop Kim, Junyoung Ahn, Youngmi Jung, Jung Min Moon, Chang Hwan Choi, Hyung-Kyoon Choi
Metabolites.2023; 14(1): 2. CrossRef - Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
Marla C Dubinsky, Fernando Magro, Flavio Steinwurz, David P Hudesman, Jami A Kinnucan, Ryan C Ungaro, Markus F Neurath, Nicole Kulisek, Jerome Paulissen, Chinyu Su, Dario Ponce de Leon, Miguel Regueiro
Inflammatory Bowel Diseases.2022;[Epub] CrossRef - Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
Gut and Liver.2022; 16(5): 764. CrossRef - Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef
- Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study
- 8,720 View
- 668 Download
- 17 Web of Science
- 15 Crossref
- Inflammatory bowel diseases
- Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
- Soo-Kyung Park, Sang Hyun Park, Chang Soo Eun, Geom Seog Seo, Jong Pil Im, Tae Oh Kim, Dong-Il Park
- Intest Res 2019;17(3):349-356. Published online February 8, 2019
- DOI: https://doi.org/10.5217/ir.2018.00064
-
Abstract
PDFPubReaderePub
- Background/Aims
A once-daily (OD) regimen of 5-aminosalicylic acid (5-ASA) was easier to comply with than a divided daily (DD) regimen, and that treatment efficacy for ulcerative colitis (UC) was not affected by the dosing regimen. This study evaluated treatment adherence of OD and DD dosing in the Korean UC patients.
Methods
This study was a prospective, multicenter, randomized trial. UC patients were enrolled who have been in remission for more than 3 months. Patients were randomly assigned to the OD or DD group in a 1:1 ratio. The primary endpoint was adherence rate measured by tablet counts and self-reported adherence rate at 3, 6, 9, and 12 months. The relapse rate was measured at 1 year.
Results
Data from the 180 patients who were randomized were analyzed. Both self-reported adherence rate and adherence rate measured by tablet counts were not different at every points, including 1 year. The patients’ satisfaction of the OD group was higher than that of the DD group (P<0.001). At 1 year, 91.2% and 95.5% of patients in the OD group and DD group had maintained clinical remission, respectively (P=0.37).
Conclusions
The adherence rates were not different between the OD group and DD group. The patients’ satisfaction was higher in the OD group than in the DD group. 5-ASA OD dosing might have the same effect as DD for the maintenance of UC remission. -
Citations
Citations to this article as recorded by- Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis
Cristiano Pagnini, Elisabetta Antonelli, Barbara Scrivo, Maria Cappello, Marco Soncini, Roberto Vassallo, Giammarco Mocci, Maria Carla Di Paolo
Journal of Personalized Medicine.2025; 15(4): 123. CrossRef - Improving Medication Adherence Levels in Inflammatory Bowel Disease (IBD) Patients: A Narrative Evidence-Based Review
Obreniokibo Amiesimaka, Kristina Aluzaite, Rhiannon Braund, Michael Schultz
Patient Preference and Adherence.2024; Volume 18: 905. CrossRef - Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 60(3): 389. CrossRef - Researching Interventions to Improve Medication Adherence in Ulcerative Colitis Patients
Mila Palma Pacheco, Flora Maria Lorenzo Fortes, Raquel Rocha dos Santos, Genoile Oliveira Santana Silva
Journal of Coloproctology.2021; 41(01): 096. CrossRef - Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef - Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs
Axel Dignass, John Waller, Joseph C. Cappelleri, Irene Modesto, Agnes Kisser, Lena Dietz, Marco DiBonaventura, Robert Wood, Melanie May, Berit Libutzki, Danielle Bargo
Journal of Medical Economics.2020; 23(4): 415. CrossRef - Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Alistair Murray, Tran M Nguyen, Claire E Parker, Brian G Feagan, John K MacDonald
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef
- Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis
- 8,850 View
- 192 Download
- 6 Web of Science
- 7 Crossref
- Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases
- Young Sun Kim, Sung-Ae Jung, Kang-Moon Lee, Soo Jung Park, Tae Oh Kim, Chang Hwan Choi, Hyun Gun Kim, Won Moon, Chang Mo Moon, Hye Kyoung Song, Soo-Young Na, Suk-Kyun Yang
- Intest Res 2017;15(3):338-344. Published online June 12, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.3.338
-
Abstract
PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/> Inflammatory bowel disease (IBD) is a chronic disabling gastrointestinal disorder that diminishes the quality of life of the affected individuals. Limited data are available regarding the impact of IBD on the daily life of Koreans.
Methods Self-administered, computer-aided, internet-based questionnaires were distributed to members of a Korean patient organization for IBD from March to April 2013, by the Korean Association for the Study of Intestinal Diseases.
Results A total of 599 patients with IBD (387 with Crohn's disease [CD] and 212 with ulcerative colitis [UC]) were enrolled. The majority of patients (81%) expressed feelings of fatigue, weakness, and being worn out in their daily lives during times of flare; this percentage was reduced to 61% during remission. Respondents were absent from work or school for an average period of 18 days because of illness, within the first 6 months; the majority of respondents (64%) felt stressed about their absence. Forty-six percent of the respondents reported having received unfair comments at work, or having suffered discrimination. Forty-seven percent of the respondents felt that IBD had negatively affected their income and earnings. Compared with patients with UC, those with CD reported a more frequent negative impact of IBD on work, or more economic burden. More than half of the respondents (61%) reported that IBD had prevented them from making or keeping friends.
Conclusions IBD significantly impacts daily life, including work, education, and social relationships. Treatment that addresses the full spectrum of life of a patient would be more effective.
-
Citations
Citations to this article as recorded by- Increased Risks for Suicide, Self-Harm, Substance Use, and Psychiatric Disorders in Adults With Inflammatory Bowel Disease: A Nationwide Study in the United States From 2007 to 2017
Chung Sang Tse, Chien-Hsiang Weng, Michelle Kwon, Courtney Benjamin Wolk, Lily A Brown, Kanika Malani, Samir A Shah, Sean D Fine
Inflammatory Bowel Diseases.2024; 30(1): 150. CrossRef - Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity
Seung Yong Shin, Hee Sung Kim, Kisung Kim, Chang Won Choi, Jung Min Moon, Jeong Wook Kim, Hyun Jin Joo, Jeongkuk Seo, Muhyeon Sung, Chang Hwan Choi
The Korean Journal of Internal Medicine.2024; 39(1): 68. CrossRef - Patient experiences in ulcerative colitis: conceptual model and review of patient-reported outcome measures
Chong Kim, Fiona L. Brown, Caroline Burk, Milena Anatchkova, Nashmel Sargalo, Ankita Kaushik
Quality of Life Research.2024; 33(5): 1373. CrossRef - Colonic Dysregulation of Major Metabolic Pathways in Experimental Ulcerative Colitis
Ji Yeon Noh, Naser Farhataziz, Michael T. Kinter, Xin Yan, Yuxiang Sun
Metabolites.2024; 14(4): 194. CrossRef - Patient Advisory Groups in Inflammatory Bowel Disease: A Collaborative Relationship Between Patients and Researchers
Linda Yoo, Mara Shapiro, Ihsan Kahveci, Isabela Hernandez, Rachael Whittemore, Tanvi Kale, Samantha Winders, Kendra Kamp
Crohn's & Colitis 360.2024;[Epub] CrossRef - A Phenomenological Investigation of Trauma in 18 Adults Living With Inflammatory Bowel Disease
Heidi Glynn, Simon R. Knowles
Clinical Nursing Research.2023; 32(1): 159. CrossRef - Interplay of broccoli/broccoli sprout bioactives with gut microbiota in reducing inflammation in inflammatory bowel diseases
Johanna Holman, Molly Hurd, Peter L. Moses, Gary M. Mawe, Tao Zhang, Suzanne L. Ishaq, Yanyan Li
The Journal of Nutritional Biochemistry.2023; 113: 109238. CrossRef - Medical consultation in ulcerative colitis: Key elements for improvement
Yago González-Lama, Elena Ricart, Ana Cábez, Pilar Fortes, Susana Gómez, Francesc Casellas
World Journal of Gastroenterology.2023; 29(6): 917. CrossRef - The relationship of major depressive disorder with Crohn's disease activity
Carolina Bortolozzo Graciolli Facanali, Carlos Walter Sobrado Junior, Renério Fraguas Junior, Marcio Roberto Facanali Junior, Lucas Rodrigues Boarini, Lucas Faraco Sobrado, Ivan Cecconello
Clinics.2023; 78: 100188. CrossRef - Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease
Eun Jin Yoo, Sang-Hoon Cho, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Yonsei Medical Journal.2023; 64(9): 541. CrossRef - The impact of gastrointestinal conditions on psychosocial factors associated with the biopsychosocial model of health: A scoping review
Elizabeth Dent, Nicola Davinson, Stephanie Wilkie
Applied Psychology: Health and Well-Being.2022; 14(2): 626. CrossRef - Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway
Yao Li, Xu Yang, Jia-ni Yuan, Rui Lin, Yun-yuan Tian, Yu-xin Li, Yan Zhang, Xu-fang Wang, Yan-hua Xie, Si-wang Wang, Xiao-hui Zheng
Frontiers in Pharmacology.2022;[Epub] CrossRef - The association between inflammatory bowel disease and mental ill health: a retrospective cohort study using data from UK primary care
Nosheen Umar, Dominic King, Joht Singh Chandan, Neeraj Bhala, Krish Nirantharakumar, Nicola Adderley, Dawit T. Zemedikun, Phil Harvey, Nigel Trudgill
Alimentary Pharmacology & Therapeutics.2022; 56(5): 814. CrossRef - Association of inflammatory bowel disease with suicidal ideation, suicide attempts, and suicide: A systematic review and meta-analysis
Qin Xiong, Fuyou Tang, Yilin Li, Fengjiao Xie, Lei Yuan, Chengjiao Yao, Ruike Wu, Juan Wang, Qiuxiang Wang, Peimin Feng
Journal of Psychosomatic Research.2022; 160: 110983. CrossRef - Modelling symptoms to suicide risk in individuals with inflammatory bowel disease
Valentina Mihajlovic, Dean A Tripp, Jill A Jacobson
Journal of Health Psychology.2021; 26(12): 2143. CrossRef - Risk of Inflammatory Bowel Disease Following Appendectomy in Adulthood
Wei-Sheng Chung, Sunny Chung, Chung-Y Hsu, Cheng-Li Lin
Frontiers in Medicine.2021;[Epub] CrossRef - Gastrointestinal microbiome, what is behind faecal microbiota transplantation?
P. Thomson, P. Núñez, R. Quera, C. Bay
New Microbes and New Infections.2021; 42: 100898. CrossRef - Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study
Jooyoung Lee, Jong Pil Im, Kyungdo Han, Jihye Kim, Hyun Jung Lee, Jaeyoung Chun, Joo Sung Kim
Gut and Liver.2020; 14(1): 89. CrossRef - Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management
G. Pellino, D. S. Keller, G. M. Sampietro, V. Annese, M. Carvello, V. Celentano, C. Coco, F. Colombo, N. Cracco, F. Di Candido, M. Franceschi, S. Laureti, G. Mattioli, L. Pio, G. Sciaudone, G. Sica, V. Villanacci, R. Zinicola, S. Leone, S. Danese, A. Spin
Techniques in Coloproctology.2020; 24(2): 105. CrossRef - Inflammatory bowel disease fatigue: an analysis of definitions, risk factors and impact and their implications for assessment and management
Doireann Ni Dhalaigh, Anna Marie Greaney, Dawn Farrell
Gastrointestinal Nursing.2020; 18(5): 42. CrossRef - Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
Jung Rock Moon, Chang Kyun Lee, Sung Noh Hong, Jong Pil Im, Byong Duk Ye, Jae Myung Cha, Sung-Ae Jung, Kang-Moon Lee, Dong Il Park, Yoon Tae Jeen, Young Sook Park, Jae Hee Cheon, Hyesung Kim, BoJeong Seo, Youngdoe Kim, Hyo Jong Kim
Gut and Liver.2020; 14(4): 459. CrossRef - Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations
Francesc Casellas, Daniel Guinard Vicens, Santiago García-López, Yago González-Lama, Federico Argüelles-Arias, Manuel Barreiro-de Acosta, Laura Marín Sánchez, Juan Manuel Mendive, Roberto Saldaña, Ana Cabez, Susana Gómez, Estíbaliz Loza
European Journal of Gastroenterology & Hepatology.2020; 32(12): 1514. CrossRef - Preconception Care Program for Women with Inflammatory Bowel Disease Using Intervention Mapping: A Protocol for Program Development
Young Jin Lee, Yeon Hee Kim, Hae Won Kim
International Journal of Environmental Research and Public Health.2020; 17(24): 9365. CrossRef - Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn’s disease
Jing Zhou, Lu-Yi Wu, Liu Chen, Ya-Jing Guo, Yi Sun, Tao Li, Ji-Meng Zhao, Chun-Hui Bao, Huan-Gan Wu, Yin Shi
World Journal of Gastroenterology.2019; 25(17): 2071. CrossRef - EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
María Chaparro, Manuel Barreiro-de Acosta, José Manuel Benítez, José Luis Cabriada, María José Casanova, Daniel Ceballos, María Esteve, Hipólito Fernández, Daniel Ginard, Fernando Gomollón, Rufo Lorente, Pilar Nos, Sabino Riestra, Montserrat Rivero, Pilar
Therapeutic Advances in Gastroenterology.2019;[Epub] CrossRef - Application of Herbaceous Medications for Inflammatory Bowel Disease as a Complementary and Alternative Therapy
Zili Lin, Huiyi Wu, Yiming Fu, Shixue Dai
Inflammatory Bowel Diseases.2019; 25(12): 1886. CrossRef - Analysis of the Nutrients and Food Products Intake of Polish Males with Ulcerative Colitis in Remission
Dominika Głąbska, Dominika Guzek, Gustaw Lech
Nutrients.2019; 11(10): 2333. CrossRef - Are there also negative effects of social support? A qualitative study of patients with inflammatory bowel disease
Alexander Palant, Wolfgang Himmel
BMJ Open.2019; 9(1): e022642. CrossRef - Reactive Oxygen Species Deficiency Due to Ncf1-Mutation Leads to Development of Adenocarcinoma and Metabolomic and Lipidomic Remodeling in a New Mouse Model of Dextran Sulfate Sodium-Induced Colitis
Lina Carvalho, Joana R. M. Gomes, Ludgero C. Tavares, Ana R. Xavier, Karel D. Klika, Rikard Holmdahl, Rui A. Carvalho, M. Margarida Souto-Carneiro
Frontiers in Immunology.2018;[Epub] CrossRef - Complementary and alternative medicine in patients with inflammatory bowel disease: A survey performed in a tertiary center in Chile
Antonia Fernández, Daniela Simian, Rodrigo Quera, Lilian Flores, Patricio Ibáñez, Jaime Lubascher, Carolina Figueroa, Udo Kronberg, Gonzalo Pizarro, Daniela Fluxá
Complementary Therapies in Medicine.2018; 40: 77. CrossRef - IBD2020 global forum: results of an international patient survey on quality of care
Peter Irving, Johan Burisch, Richard Driscoll, Mats Olsson, John R Fullarton, Barry S Rodgers-Gray, Simon PL Travis
Intestinal Research.2018; 16(4): 537. CrossRef - Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Gut and Liver.2018; 12(5): 544. CrossRef
- Increased Risks for Suicide, Self-Harm, Substance Use, and Psychiatric Disorders in Adults With Inflammatory Bowel Disease: A Nationwide Study in the United States From 2007 to 2017
- 7,347 View
- 94 Download
- 32 Web of Science
- 32 Crossref
- Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam
- Eun Ji Lee, Tae Oh Kim, Geun Am Song, Jong hun Lee, Hyung Wook Kim, Sam Ryong Jee, Seun Ja Park, Hyun Jin Kim, Jong Ha Park
- Intest Res 2016;14(1):30-36. Published online January 26, 2016
- DOI: https://doi.org/10.5217/ir.2016.14.1.30
-
Abstract
PDFPubReaderePub
<b>Background/Aims</b><br/> Crohn's disease (CD) is a chronic inflammatory bowel disease that presents with variable features and repeated disease aggravation. The incidence of CD is increasing in Korea. We evaluated the clinical features of CD in a study population in Busan and Gyeongnam, Korea.
Methods A hospital-based analysis included 619 patients diagnosed with CD between March 1986 and February 2013 from seven tertiary care hospitals in Busan and Gyeongnam. Individual case records were reviewed with regard to age at diagnosis, sex, disease location, disease behavior, and medical and surgical treatments received during the follow-up period.
Results The cumulative frequency of patients diagnosed with CD revealed a continued increase in the number of cases reported yearly. The male-to-female ratio was 2.5:1 and the median age at diagnosis was 24 years. At diagnosis, 114 (18.4%) had isolated small bowel disease, 144 (23.3%) had isolated colonic disease, and 358 patients (57.8%) presented with disease in the small bowel and colon. The number of patients presenting with stricturing or penetrating disease behavior was 291 (47%) at the final evaluation. In total, 111 (17.9%) patients underwent intestinal resections.
Conclusions A continued increase in the number of patients diagnosed with CD was found in Busan and Gyeongnam as observed in other regions. We report results similar to that of other Korean studies in terms of sex distribution, age, and location of disease.
-
Citations
Citations to this article as recorded by- Association between inflammatory bowel disease and osteoporosis in European and East Asian populations: exploring causality, mediation by nutritional status, and shared genetic architecture
Jian Kang, Xize Wu, Yue Li, Shuangli Zhao, Shixuan Wang, Dongdong Yu
Frontiers in Immunology.2024;[Epub] CrossRef - Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef - NF-kappa B activation correlates with disease phenotype in Crohn’s disease
Yoo Min Han, Jaemoon Koh, Ji Won Kim, Changhyun Lee, Seong-Joon Koh, ByeongGwan Kim, Kook Lae Lee, Jong Pil Im, Joo Sung Kim, Gernot Sellge
PLOS ONE.2017; 12(7): e0182071. CrossRef - Are there interregional differences in the epidemiology and clinical characteristics of Crohn's disease in the Asia-Pacific region?
Sinwon Lee, Byong Duk Ye
Intestinal Research.2016; 14(1): 2. CrossRef - Changing epidemiological trends of inflammatory bowel disease in Asia
Wee Khoon Ng, Sunny H. Wong, Siew C. Ng
Intestinal Research.2016; 14(2): 111. CrossRef
- Association between inflammatory bowel disease and osteoporosis in European and East Asian populations: exploring causality, mediation by nutritional status, and shared genetic architecture
- 5,376 View
- 47 Download
- 5 Web of Science
- 5 Crossref
Statement
- Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)
- Kang-Moon Lee, You Sun Kim, Geom Seog Seo, Tae Oh Kim, Suk-Kyun Yang, IBD Study Group of the Korean Association for the Study of Intestinal Diseases
- Intest Res 2015;13(3):193-207. Published online June 9, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.3.193
-
Abstract
PDFPubReader
<b>Background/Aims</b><br/> For decades, thiopurines have been the mainstay of inflammatory bowel disease (IBD) treatment and will play an important role in the future. However, complex metabolism and various side effects limit the use of these potent drugs in clinical practice. The Korean Association for the Study of Intestinal Diseases developed a set of consensus statements with the aim of guiding clinicians on the appropriate use of thiopurines in the management of IBD.
Methods Sixteen statements were initially drafted by five committee members. The quality of evidence and classification of recommendation were assessed according to the Grading of Recommendations Assessment, Development and Evaluation system. The statements were then circulated to IBD experts in Korea for review, feedback, and then finalized and accepted by voting at the consensus meeting.
Results The consensus statements comprised four parts: (1) pre-treatment evaluation and management strategy, including value of thiopurine S-methyltransferase screening, dosing schedule, and novel biomarkers for predicting thiopurine-induced leukopenia; (2) treatment with thiopurines with regards to optimal duration of thiopurine treatment and long-term outcomes of combination therapy with anti-tumor necrosis factors; (3) safety of thiopurines, especially during pregnancy and lactation; and (4) monitoring side effects or efficacy of therapy using biomarkers.
Conclusions Thiopurines are an effective treatment option for patients with IBD. Management decisions should be individualized according to the risk of relapse and adverse events.
-
Citations
Citations to this article as recorded by- Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
Yu Kyung Jun, Eunjeong Ji, Hye Ran Yang, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef - Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy
Ahmed B. Bayoumy, A. R. Ansari, C. J. J. Mulder, K. Schmiegelow, Timothy Florin, N. K. H. De Boer
Clinical Pharmacokinetics.2024; 63(8): 1089. CrossRef - Azathioprine for people with multiple sclerosis
Ben Ridley, Francesco Nonino, Elisa Baldin, Ilaria Casetta, Gerardo Iuliano, Graziella Filippini
Cochrane Database of Systematic Reviews.2024;[Epub] CrossRef - Inflammatory Bowel Disease: Pathophysiology, Treatment, and Disease Modeling
Jiryeon Jang, Sehoon Jeong
BioChip Journal.2023; 17(4): 403. CrossRef - Association of genetic polymorphism of NUDT15, TPMT and ITPA gene in the toxicity and efficacy of azathioprine-based regimen in Egyptian inflammatory bowel disease patients
Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub] CrossRef - A review article of inflammatory bowel disease treatment and pharmacogenomics
Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub] CrossRef - Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review
Devendra Desai, Anuraag Jena, Vishal Sharma, Toshifumi Hibi
Expert Review of Clinical Pharmacology.2023; 16(7): 643. CrossRef - Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
Yoon-Zi Kim, Ben Kang, Eun-Sil Kim, Yiyoung Kwon, Yon-Ho Choe, Mi-Jin Kim
Biomedicines.2023; 11(9): 2575. CrossRef - Effect of NUDT15 polymorphisms on early hematological safety of low‐dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study
Xingli Zhou, Liangliang Cheng, Yiyi Wang, Hui Gou, Ke Ju, TianJiao Lan, Tongying Zhan, GaoJie Li, Yuanxia Gu, Yeting Sun, Yan Xu, Yukun Sun, Yanhong Zhou, Wei Li
The Journal of Dermatology.2022; 49(4): 402. CrossRef - Use of thiopurines in inflammatory bowel disease: an update
Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, Amit Kumar Dutta, Abhinav Anand, Charles N. Bernstein, Devendra Desai, C. Ganesh Pai, Govind Makharia, Harsh Vardhan Tevethia, Joyce WY Mak, Kirandeep Kaur, Kiran Peddi, Mukesh Kumar Ranjan, Perttu Arkkila, Ra
Intestinal Research.2022; 20(1): 11. CrossRef - Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder
Wenjuan Huang, Liang Wang, Junhui Xia, Wenyu Li, Min Wang, Jian Yu, Qinying Li, Bei Wang, Juyuan Pan, Lei Du, Jianhua Ma, Hongmei Tan, Xuechun Chang, Chuanzhen Lu, Chongbo Zhao, Jiahong Lu, Lei Zhou, Jingzi ZhangBao, Chao Quan
European Journal of Neurology.2022; 29(8): 2343. CrossRef - Minimal risk of lymphoma and non‐melanoma skin cancer despite long‐term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India
Mukesh Kumar Ranjan, Bhaskar Kante, Sudheer Kumar Vuyyuru, Peeyush Kumar, Sandeep K Mundhra, Rithvik Golla, Raju Sharma, Peush Sahni, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
Journal of Gastroenterology and Hepatology.2022; 37(8): 1544. CrossRef - NUDT15Genotyping in Thiopurine Drug Therapy
Jong Kwon Lee, Rihwa Choi, Soo-Youn Lee
Laboratory Medicine Online.2022; 12(4): 217. CrossRef - Association of genetic variants in TPMT, ITPA, and NUDT15 with azathioprine-induced myelosuppression in southwest china patients with autoimmune hepatitis
Qiang Miao, Lin Yan, Yanhong Zhou, Yi Li, Yuangao Zou, Lanlan Wang, Yangjuan Bai, Junlong Zhang
Scientific Reports.2021;[Epub] CrossRef - Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef - Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease
Kang Chao, Yibiao Huang, Xia Zhu, Jian Tang, Xueding Wang, Lang Lin, Huili Guo, Caibin Zhang, Miao Li, Qingfan Yang, Jie Huang, Lingna Ye, Pinjin Hu, Min Huang, Qian Cao, Xiang Gao
Alimentary Pharmacology & Therapeutics.2021; 54(9): 1124. CrossRef - NUDT15: A bench to bedside success story
Ann M. Moyer
Clinical Biochemistry.2021; 92: 1. CrossRef - Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations
Kanyarat Khaeso, Sariya Udayachalerm, Patcharee Komvilaisak, Su-on Chainansamit, Kunanya Suwannaying, Napat Laoaroon, Pitchayanan Kuwatjanakul, Nontaya Nakkam, Chonlaphat Sukasem, Apichaya Puangpetch, Wichittra Tassaneeyakul, Nathorn Chaiyakunapruk
Frontiers in Pharmacology.2021;[Epub] CrossRef - Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef - Sexual Dysfunction and Fertility Problems in Men with Inflammatory Bowel Disease
Yong Eun Park, Tae Oh Kim
The World Journal of Men's Health.2020; 38(3): 285. CrossRef - Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases
Ji Young Chang, Soo Jung Park, Eun Suk Jung, Sung-Ae Jung, Chang Mo Moon, Jaeyoung Chun, Jae Jun Park, Eun Sun Kim, Yehyun Park, Tae-Il Kim, Won Ho Kim, Jae Hee Cheon
Clinical Gastroenterology and Hepatology.2020; 18(9): 2010. CrossRef - Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Hiroshi Nakase
Gut and Liver.2020; 14(1): 7. CrossRef - Adjustment of azathioprine dose should be based on a lower 6‐TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers
Ben Kang, Tae Jun Kim, Jaeyoung Choi, Sun‐Young Baek, Soohyun Ahn, Rihwa Choi, Soo‐Youn Lee, Yon Ho Choe
Alimentary Pharmacology & Therapeutics.2020; 52(3): 459. CrossRef - NUDT15 genotyping during azathioprine treatment in patients with inflammatory bowel disease: implications for a dose-optimization strategy
Ye Xu, Yu-Qi Qiao, Han-Yang Li, Mi Zhou, Chen-Wen Cai, Jun Shen, Zhi-Hua Ran
Gastroenterology Report.2020; 8(6): 437. CrossRef -
Complete remission of refractory pemphigus vulgaris in a Chinese patient with mutated
NUDT15
by combination of minimal doses of azathioprine and prednisone
Xing‐Li Zhou, Tong‐Ying Zhan, Yan‐Hong Zhou, Krista Shrestha, Tian‐Jiao Lan, Wei Li
Dermatologic Therapy.2020;[Epub] CrossRef - Prevention of thiopurine-induced early leukopenia in a Korean pediatric patient with Crohn’s disease who turned out to possess homozygous mutations in NUDT15 R139C
Jaewoan Bae, Byung-Ho Choe, Ben Kang
Yeungnam University Journal of Medicine.2020; 37(4): 332. CrossRef - NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine‐induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India
Rupa Banerjee, Vishnubhotla Venkata Ravikanth, Partha Pal, Govardhan Bale, Urmila Steffie Avanthi, Idan Goren, B. Ganesh Girish, Sasikala Mitnala, D. Nageshwar Reddy
Alimentary Pharmacology & Therapeutics.2020; 52(11-12): 1683. CrossRef - Improving the quality of care for inflammatory bowel disease
Byong Duk Ye, Simon Travis
Intestinal Research.2019; 17(1): 45. CrossRef - NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis
Xiaoli Fan, Dandan Yin, Ruoting Men, Heng Xu, Li Yang
Frontiers in Pharmacology.2019;[Epub] CrossRef - Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics
Ji Young Chang, Jae Hee Cheon
Digestive Diseases and Sciences.2019; 64(9): 2395. CrossRef - Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn’s disease patients
Xia Zhu, Kang Chao, Miao Li, Wen Xie, Hong Zheng, Jin-Xin Zhang, Pin-Jin Hu, Min Huang, Xiang Gao, Xue-Ding Wang
World Journal of Gastroenterology.2019; 25(38): 5850. CrossRef - How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
You Sun Kim
The Korean Journal of Gastroenterology.2018; 71(2): 74. CrossRef - Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis
Sarah Cargnin, Armando A. Genazzani, Pier Luigi Canonico, Salvatore Terrazzino
Pharmacological Research.2018; 135: 102. CrossRef - Treatment of Autoimmune Bullous Disorders in Pregnancy
Carolyn J. Kushner, Josef Symon S. Concha, Victoria P. Werth
American Journal of Clinical Dermatology.2018; 19(3): 391. CrossRef - Characteristics and management of patients with inflammatory bowel disease between a secondary and tertiary hospitals: a propensity score analysis
Ki Hwan Song, Eun Soo Kim, Yoo Jin Lee, Byung Ik Jang, Kyeong Ok Kim, Sang Gyu Kwak, Hyun Seok Lee
Intestinal Research.2018; 16(2): 216. CrossRef - Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
Intestinal Research.2018; 16(1): 4. CrossRef - Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease
Hong-Hui Wang, Ying He, Hong-Xian Wang, Cheng-Ling Liao, Yu Peng, Li-Jian Tao, Wei Zhang, Hui-Xiang Yang
World Journal of Gastroenterology.2018; 24(8): 941. CrossRef - NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients
Xiang Fei, Qing Shu, Huaijun Zhu, Bingzhu Hua, Shiying Wang, Ling Guo, Yun Fang, Weihong Ge
Frontiers in Pharmacology.2018;[Epub] CrossRef - Pharmacotherapy of ulcerative colitis – current status and emerging trends
Hilal Ahmad, Vijay L. Kumar
Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(6): 581. CrossRef - Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
Journal of Gastroenterology and Hepatology.2018; 33(1): 20. CrossRef - Postoperative course of Crohn disease according to timing of bowel resection
Ji Min Lee, Kang-Moon Lee, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, Dong Soo Han, Chang Kyun Lee, Hyun-Ju Park
Medicine.2018; 97(16): e0459. CrossRef - Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
Sheng Zhang Lim, Eng Wee Chua
Frontiers in Pharmacology.2018;[Epub] CrossRef - Changing treatment paradigms for the management of inflammatory bowel disease
Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
The Korean Journal of Internal Medicine.2018; 33(1): 28. CrossRef - NUDT15,FTO, andRUNX1genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
Toshiyuki Sato, Tetsuya Takagawa, Yoichi Kakuta, Akihiro Nishio, Mikio Kawai, Koji Kamikozuru, Yoko Yokoyama, Yuko Kita, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Kazutoshi Hori, Hiroki Ikeuchi, Shiro Nakamura
Intestinal Research.2017; 15(3): 328. CrossRef - Second Korean Guideline for the Management of Ulcerative Colitis
Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
The Korean Journal of Gastroenterology.2017; 69(1): 1. CrossRef - Adalimumab or infliximab: which is better for perianal fistula in Crohn's disease?
Jong Pil Im
Intestinal Research.2017; 15(2): 147. CrossRef - Second Korean guidelines for the management of ulcerative colitis
Chang Hwan Choi, Won Moon, You Sun Kim, Eun Soo Kim, Bo-In Lee, Yunho Jung, Yong Sik Yoon, Heeyoung Lee, Dong Il Park, Dong Soo Han
Intestinal Research.2017; 15(1): 7. CrossRef - Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease
Kang Chao, Xueding Wang, Qian Cao, Jiaming Qian, Kaichun Wu, Xia Zhu, Hong Yang, Jie Liang, Lang Lin, Zicheng Huang, Yu Zhang, Yibiao Huang, Yinghao Sun, Xianmin Xue, Min Huang, Pinjin Hu, Ping Lan, Xiang Gao
Inflammatory Bowel Diseases.2017; 23(9): 1592. CrossRef - Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
Abhinav Vasudevan, Peter R Gibson, Daniel R van Langenberg
World Journal of Gastroenterology.2017; 23(35): 6385. CrossRef - Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
Chang Soo Eun
Gut and Liver.2017; 11(1): 3. CrossRef - Second Korean Guidelines for the Management of Crohn's Disease
Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
The Korean Journal of Gastroenterology.2017; 69(1): 29. CrossRef - Second Korean guidelines for the management of Crohn's disease
Jae Jun Park, Suk-Kyun Yang, Byong Duk Ye, Jong Wook Kim, Dong Il Park, Hyuk Yoon, Jong Pil Im, Kang Moon Lee, Sang Nam Yoon, Heeyoung Lee
Intestinal Research.2017; 15(1): 38. CrossRef - Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study
Sang Hyoung Park, Sung Wook Hwang, Min Seob Kwak, Wan Soo Kim, Jeong-Mi Lee, Ho-Su Lee, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
Digestive Diseases and Sciences.2016; 61(7): 2060. CrossRef - Measurement of red blood cell 6-thioguanine nucleotide is beneficial in azathioprine maintenance therapy of Chinese Crohn’s disease patients
Qiuyuan Liu, Yanyan Wang, Qiao Mei, Wei Han, Jing Hu, Naizhong Hu
Scandinavian Journal of Gastroenterology.2016; 51(9): 1093. CrossRef - NUDT15 polymorphisms are better than thiopurine S‐methyltransferase as predictor of risk for thiopurine‐induced leukopenia in Chinese patients with Crohn's disease
X. Zhu, X.‐D. Wang, K. Chao, M. Zhi, H. Zheng, H.‐L. Ruan, S. Xin, N. Ding, P.‐J. Hu, M. Huang, X. Gao
Alimentary Pharmacology & Therapeutics.2016; 44(9): 967. CrossRef - Influences ofXDHgenotype by gene–gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn’s disease
Soo-Kyung Park, Myunghee Hong, Byong Duk Ye, Kyung-Jo Kim, Sang Hyoung Park, Dong-Hoon Yang, Sung-Wook Hwang, Min Seob Kwak, Ho-Su Lee, Kyuyoung Song, Suk-Kyun Yang
Scandinavian Journal of Gastroenterology.2016; 51(6): 684. CrossRef - Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea
Ho-Su Lee, Jaewon Choe, Hyo Jeong Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
Intestinal Research.2016; 14(3): 258. CrossRef - Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease
Ho-Su Lee, Kyung-Wook Jo, Tae Sun Shim, Jin Woo Song, Hyo Jeong Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Jin-Ho Kim, Suk-Kyun Yang
Journal of Crohn's and Colitis.2015; 9(11): 1053. CrossRef
- Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
- 13,134 View
- 95 Download
- 55 Web of Science
- 58 Crossref
Review
- Epigenetic Alterations in Inflammatory Bowel Disease and Cancer
- Joo Mi Yi, Tae Oh Kim
- Intest Res 2015;13(2):112-121. Published online April 27, 2015
- DOI: https://doi.org/10.5217/ir.2015.13.2.112
-
Abstract
PDFPubReader
Overwhelming evidences supports the idea that inflammatory bowel disease (IBD) is caused by a complex interplay between genetic alterations of multiple genes and an aberrant interaction with environmental factors. There is growing evidence that epigenetic factors can play a significant part in the pathogenesis of IBD. Significant effort has been invested in uncovering genetic and epigenetic factors, which may increase the risk of IBD, but progress has been slow, and few IBD-specific factors have been detected so far. It has been known for decades that DNA methylation is the most well studied epigenetic modification, and analysis of DNA methylation is leading to a new generation of cancer biomarkers. Therefore, in this review, we summarize the role of DNA methylation alteration in IBD pathogenesis, and discuss specific genes or genetic loci using recent molecular technology advances. Here, we suggest that DNA methylation should be studied in depth to understand the molecular pathways of IBD pathogenesis, and discuss epigenetic studies of IBD that may have a significant impact on the field of IBD research.
-
Citations
Citations to this article as recorded by- Personalized Medicine for IBD Patients
Nina Fadeeva, Igor Khatkov, Natalia Bodunova, Oleg Knyazev, Dmitry Bordin, Asfold Parfenov, Karina Nikolskaya, Sergey Nikolaev, Konstantin Rumyantsev, Vera Polyakova, Tatiana Yanova
BioNanoScience.2023; 13(1): 330. CrossRef - Epigenetic Changes and Its Intervention in Age-Related Neurodegenerative Diseases
Nuraqila Mohd Murshid, Faridah Aminullah Lubis, Suzana Makpol
Cellular and Molecular Neurobiology.2022; 42(3): 577. CrossRef - Role of diet and nutrition in inflammatory bowel disease
Marina Moreira de Castro, Lívia Bitencourt Pascoal, Karine Mariane Steigleder, Beatriz Piatezzi Siqueira, Ligiana Pires Corona, Maria de Lourdes Setsuko Ayrizono, Marciane Milanski, Raquel Franco Leal
World Journal of Experimental Medicine.2021; 11(1): 1. CrossRef - Genome-Wide Analysis of the DNA Methylation Profile Identifies the Fragile Histidine Triad (FHIT) Gene as a New Promising Biomarker of Crohn’s Disease
Tae-Oh Kim, Dong-Il Park, Yu Han, Keunsoo Kang, Sae-Gwang Park, Hae Park, Joo Yi
Journal of Clinical Medicine.2020; 9(5): 1338. CrossRef - Aberrant methylation and microRNA-target regulation are associated with downregulated NEURL1B: a diagnostic and prognostic target in colon cancer
Jiaxin Liu, Zhao Liu, Xiaozhi Zhang, Yanli Yan, Shuai Shao, Demao Yao, Tuotuo Gong
Cancer Cell International.2020;[Epub] CrossRef - Effect of Perfluorooctanoic Acid on the Epigenetic and Tight Junction Genes of the Mouse Intestine
Faizan Rashid, Saeed Ahmad, Joseph Maria Kumar Irudayaraj
Toxics.2020; 8(3): 64. CrossRef - Epigenetics, DNA Organization, and Inflammatory Bowel Disease
Greeshma Ray, Michelle S Longworth
Inflammatory Bowel Diseases.2019; 25(2): 235. CrossRef - Impaired nutritional status in outpatients in remission or with active Crohn's disease – classified by objective endoscopic and imaging assessments
Marina Moreira de Castro, Ligiana Pires Corona, Lívia Bitencourt Pascoal, Bruno Lima Rodrigues, Maria de Lourdes Setsuko Ayrizono, Claudio Saddy Rodrigues Coy, Raquel Franco Leal, Marciane Milanski
Clinical Nutrition ESPEN.2019; 33: 60. CrossRef - Hepatitis B Virus Infection Is Independently Associated With Advanced Colorectal Adenoma
Su Hwan Kim, Ji Won Kim, Kook Lae Lee, Seohui Lee, Seong-Joon Koh, Ji Bong Jeong, Byeong Gwan Kim
The American Journal of the Medical Sciences.2018; 356(2): 141. CrossRef - Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Haiming Fang, Lian Fu, Jiajia Wang
BioMed Research International.2018; 2018: 1. CrossRef - Epigenetic modulation of intestinal Na+/H+ exchanger-3 expression
Anoop Kumar, Pooja Malhotra, Hayley Coffing, Shubha Priyamvada, Arivarasu N. Anbazhagan, Harish R. Krishnan, Ravinder K. Gill, Waddah A. Alrefai, David P. Gavin, Subhash C. Pandey, Pradeep K. Dudeja, Seema Saksena
American Journal of Physiology-Gastrointestinal and Liver Physiology.2018; 314(3): G309. CrossRef - Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
Chang Soo Eun
Intestinal Research.2017; 15(2): 145. CrossRef - Lack of Aberrant Methylation in an Adjacent Area of Left-Sided Colorectal Cancer
Otgontuya Sambuudash, Hyun-Soo Kim, Mee Yon Cho
Yonsei Medical Journal.2017; 58(4): 749. CrossRef - The colon revisited or the key to wellness, health and disease
C.A. Gonzalez-Correa, E. Mulett-Vásquez, D.A. Miranda, C.H. Gonzalez-Correa, P.A. Gómez-Buitrago
Medical Hypotheses.2017; 108: 133. CrossRef - The contribution of long non-coding RNAs in Inflammatory Bowel Diseases
Eirini Zacharopoulou, Maria Gazouli, Maria Tzouvala, Antonios Vezakis, George Karamanolis
Digestive and Liver Disease.2017; 49(10): 1067. CrossRef - Epigenetic silencing of NDRG2 promotes colorectal cancer proliferation and invasion
Sung Noh Hong, Sung Jin Kim, Eun‐Ran Kim, Dong Kyung Chang, Young‐Ho Kim
Journal of Gastroenterology and Hepatology.2016; 31(1): 164. CrossRef - Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis
Italia Loddo, Claudio Romano
Frontiers in Immunology.2015;[Epub] CrossRef - The genetic architecture of inflammatory bowel disease
Isabelle Cleynen, Séverine Vermeire
Current Opinion in Gastroenterology.2015;[Epub] CrossRef - Epigenetic Modification and Its Role in Alzheimer's Disease
Yi-Ping Zhu, Ya Feng, Te Liu, Yun-Cheng Wu
Integrative Medicine International.2015; 2(1-2): 63. CrossRef
- Personalized Medicine for IBD Patients
- 20,431 View
- 68 Download
- 26 Web of Science
- 19 Crossref
Original Articles
- The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
- Hyun Il Seo, Dong Il Park, Tae Oh Kim, You Sun Kim, Suck-Ho Lee, Ji Won Kim, Jae Hak Kim, Jeong Eun Shin
- Intest Res 2014;12(3):214-220. Published online July 25, 2014
- DOI: https://doi.org/10.5217/ir.2014.12.3.214
-
Abstract
PDFPubReaderePub
<b>Background/Aims</b><br/> Infliximab was introduced recently as a rescue therapy for ulcerative colitis (UC) patients refractory to conventional treatments such as therapy with 5-amiono salicylic acids (5-ASA), immune modulators, and corticosteroids. However, there is insufficient data about its efficacy and safety in Korea.
Methods From 7 tertiary referral hospitals, 33 patients who were treated with infliximab for moderate to severe (Mayo score 6-12) UC refractory to conventional treatment were recruited to this study. Clinical remission was defined as a total Mayo score of 2 or lower and every subscore less than 2. Partial response was defined as a decrease of Mayo score at least 3 points from baseline.
Results Twenty-three patients (69.7%) showed clinical remission and 29 patients (87.8%) showed partial response in the observation period. When the remission and non-remission groups were compared in univariate analysis, only a higher total Mayo score at base line (11.0±0.9 vs. 9.9±1.5;
P =0.04) was related to remission. The remission maintenance rate decreased with time in the Kaplan-Meier analysis. Two patients experienced re-remission after the first remission followed by aggravation during infliximab treatment. Three patients stopped infliximab treatment owing to adverse events including rhabdomyolysis, pneumonia, and fever of unknown origin.Conclusions If there is no choice except surgery for UC patients refractory to conventional treatment, infliximab is an effective and relatively safe treatment option for these patients in Korea.
-
Citations
Citations to this article as recorded by- Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
Middle East Journal of Digestive Diseases.2019; 12(1): 12. CrossRef - Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef - Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea
Hyungil Seo, Kiju Chang, Sun-Ho Lee, Eun-Mi Song, Gwang-Un Kim, Myeongsook Seo, Ho-Su Lee, Sung-Wook Hwang, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Scandinavian Journal of Gastroenterology.2017; 52(8): 857. CrossRef - Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin
Kymberley Thorne, Laith Alrubaiy, Ashley Akbari, David G. Samuel, Sian Morrison-Rees, Stephen E. Roberts
European Journal of Gastroenterology & Hepatology.2016; 28(4): 369. CrossRef - Efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Yoon Suk Jung, Dong Il Park, Young Ho Kim, Ji Hyun Lee, Pyoung Ju Seo, Jae Hee Cheon, Hyoun Woo Kang, Ji Won Kim
Journal of Gastroenterology and Hepatology.2015; 30(12): 1705. CrossRef - Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future
Jung Won Lee, Jong Pil Im, Jae Hee Cheon, You Sun Kim, Joo Sung Kim, Dong Soo Han
Intestinal Research.2015; 13(3): 213. CrossRef - Circulating Ghrelin Levels and Obestatin/Ghrelin Ratio as a Marker of Activity in Ulcerative Colitis
Ja Young Jung, Ji Bong Jeong, Ji Won Kim, Su Hwan Kim, Seong-Joon Koh, Byeong Gwan Kim, Kook Lae Lee
Intestinal Research.2015; 13(1): 68. CrossRef - How to Write Bibliographies for Citing Domestic Academic Resources
Hyun Jung Yi
The Korean Journal of Gastroenterology.2015; 65(1): 70. CrossRef - Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?
Chang Soo Eun, Dong Soo Han
Gut and Liver.2015;[Epub] CrossRef - Current and Emerging Biologics for Ulcerative Colitis
Sung Chul Park, Yoon Tae Jeen
Gut and Liver.2015; 9(1): 18. CrossRef
- Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
- 5,641 View
- 40 Download
- 8 Web of Science
- 10 Crossref
- Comparison of the Efficacy and Tolerability between Same-day Picosulfate and Split-dose Polyethylene Glycol Bowel Preparation for Afternoon Colonoscopy: A Prospective, Randomized, Investigator-blinded Trial
- Mi Seon Kang, Tae Oh Kim, Eun Hee Seo, Da Kyung Jung, Mo Se Kim, Nae Yun Heo, Jong Ha Park, Seung Ha Park, Young Soo Moon
- Intest Res 2014;12(1):53-59. Published online January 28, 2014
- DOI: https://doi.org/10.5217/ir.2014.12.1.53
-
Abstract
PDFPubReader
<b>Background/Aims</b><br/> In the present study, we evaluated the efficacy and tolerability between same-day bowel preparation protocols using 2 sachets of Picosulfate and a 4 L split-dose polyethylene glycol (PEG) bowel preparation for afternoon colonoscopy.
Methods The study had a single-center, prospective, randomized, and investigator-blinded, non-inferiority design. We evaluated bowel preparation quality according to the Ottawa scale, patient tolerability, compliance, incidence of adverse events, sleep quality, and polyp/adenoma detection rate.
Results Among the 196 patients analyzed (mean age, 55.3 years; 50.3% men), 97 received the same-day regimen of 2 sachets of picosulfate (group A) and 99 received the 4 L split-dose PEG regimen (group B). The Ottawa score of the total colon was 4.05±1.56 in group A and 3.80±1.55 in group B (
P =0.255). The proportion of patients having adequate bowel preparation in the same-day picosulfate group (61.5%) was slightly less than the 4 L PEG group (71.3%); however, the difference was not statistically significant (P =0.133). Tolerability of the group A regimen was superior to that of the group B regimen (P <0.000). The same-day picosulfate regimen was associated with fewer adverse events, such as abdominal bloating (P =0.037) and better sleep quality (P <0.000).Conclusions The same-day picosulfate regimen and the 4 L split-dose PEG regimen had similar efficacy in bowel preparation for afternoon colonoscopy. However, the same-day picosulfate regimen was easier to administer, produced fewer adverse events, and enabled better sleep quality.
-
Citations
Citations to this article as recorded by- Efficacy and safety of same‐day preparation with sodium picosulfate plus magnesium citrate on the day of colonoscopy for bowel preparation: Multicenter, single‐arm, open‐label study
Hitomi Hori, Nobuaki Ikezawa, Shinwa Tanaka, Chise Ueda, Mizuho Fujisawa, Shinya Hoki, Hiroshi Tanabe, Ryosuke Ishida, Norihiro Okamoto, Hiroshi Takayama, Haruka Miyazaki, Hiroya Sakaguchi, Masato Kinoshita, Hirofumi Abe, Tetsuya Yoshizaki, Makoto Ooi, Ma
Journal of Gastroenterology and Hepatology.2024; 39(10): 2151. CrossRef - Comparison Between Same-Day and Split-Dose Preparations with Sodium Picosulfate/Magnesium Citrate: A Randomized Noninferiority Study
Chen-Ta Yang, Hsuan-Yuan Huang, Hsu-Heng Yen, Chia-Wei Yang, Yang-Yuan Chen, Siou-Ping Huang
Digestive Diseases and Sciences.2022; 67(8): 3964. CrossRef - Efectividad y tolerabilidad de tres tipos de productos de preparación para colonoscopia
Luis Fernando Roldán Molina, Lina María Roldán Delfino, Sandra Milena León Ramírez, Edilberto Elías Nuñez Cabarcas, Hilda María Pérez Useche, Antonio José Restrepo Peláez, María Adelaida Saffón Abad, Julio Eduardo Zuleta Muñoz, Juan Nicolás Zuluaga Aguila
Revista colombiana de Gastroenterología.2021; 36(3): 334. CrossRef - A prospective randomized clinical study evaluating the efficacy and compliance of oral sulfate solution and 2-L ascorbic acid plus polyethylene glycol
Ki Hwan Kwon, Ji Ae Lee, Yun Jeong Lim, Beom Jae Lee, Moon Kyung Joo, Yu Ra Sim, Wonjae Choi, Taehyun Kim, Ji Yoon Kim, Ei Rie Cho, Yoon Tae Jeen, Jong-Jae Park
The Korean Journal of Internal Medicine.2020; 35(4): 873. CrossRef - A randomized controlled trial on comparison of colon cleansing for colonoscopy bowel preparation using one-day or two-day regimen methods
Saleh Azadbakht, Morteza Azadbakht, Salehe Azadbakht, Alireza Esmaili, Parisa Rahmani
International Journal of Surgery Open.2020; 27: 140. CrossRef - Split-dose vs same-day bowel preparation for afternoon colonoscopies: A meta-analysis of randomized controlled trials
Nasim Parsa, Eric A Grisham, Courtney J Cockerell, Michelle L Matteson-Kome, Ramakrishna V Bysani, Sami Samiullah, Douglas L Nguyen, Veysel Tahan, Yezaz A Ghouri, Srinivas R Puli, Matthew L Bechtold
World Journal of Meta-Analysis.2020; 8(6): 461. CrossRef - Split-dose vs same-day bowel preparation for afternoon colonoscopies: A meta-analysis of randomized controlled trials
Nasim Parsa, Eric A Grisham, Courtney J Cockerell, Michelle L Matteson-Kome, Ramakrishna V Bysani, Sami Samiullah, Douglas L Nguyen, Veysel Tahan, Yezaz A Ghouri, Srinivas R Puli, Matthew L Bechtold
World Journal of Meta-Analysis.2020; 8(6): 462. CrossRef - Same-Day Regimen as an Alternative to Split Preparation for Colonoscopy: A Systematic Review with Meta-Analysis
Cristina Bucci, Fabiana Zingone, Pietro Schettino, Clelia Marmo, Riccardo Marmo
Gastroenterology Research and Practice.2019; 2019: 1. CrossRef - The Efficacy of Split-Dose Bowel Preparations for Polyp Detection: A Systematic Review and Meta-Analysis
Kathleen Zawaly, Colin Rumbolt, Ahmed M. Abou-Setta, Christine Neilson, Rasheda Rabbani, Ryan Zarychanski, Harminder Singh
American Journal of Gastroenterology.2019; 114(6): 884. CrossRef - Comparison of Bowel Cleansing Efficacy, Safety, Bowel Movement Kinetics, and Patient Tolerability of Same-Day and Split-Dose Bowel Preparation Using 4 L of Polyethylene Glycol: A Prospective Randomized Study
Myeongsook Seo, Tae-Geun Gweon, Cheal Wung Huh, Jeong Seon Ji, Hwang Choi
Diseases of the Colon & Rectum.2019; 62(12): 1518. CrossRef - Same-day Versus Split-dose Bowel Preparation Before Colonoscopy
Yuan-Lung Cheng, Kuang-Wei Huang, Wei-Chih Liao, Jiing-Chyuan Luo, Keng-Hsin Lan, Chien-Wei Su, Yuan-Jen Wang, Ming-Chih Hou
Journal of Clinical Gastroenterology.2018; 52(5): 392. CrossRef - Polyp detection rate may predict adenoma detection rate: a meta-analysis
Yaron Niv
European Journal of Gastroenterology & Hepatology.2018; 30(3): 247. CrossRef - Bowel Preparations Administered the Morning of Colonoscopy Provide Similar Efficacy to a Split Dose Regimen
Danny J. Avalos, Fernando J. Castro, Marc J. Zuckerman, Tara Keihanian, Andrew C. Berry, Benjamin Nutter, Daniel A. Sussman
Journal of Clinical Gastroenterology.2018; 52(10): 859. CrossRef - Sodium picosulphate or polyethylene glycol before elective colonoscopy in outpatients? A systematic review and meta-analysis
Rodrigo Silva de Paula Rocha, Igor Braga Ribeiro, Diogo Turiani Hourneaux de Moura, Wanderley Marques Bernardo, Maurício Kazuyoshi Minata, Flávio Hiroshi Ananias Morita, Júlio Cesar Martins Aquino, Elisa Ryoka Baba, Nelson Tomio Miyajima, Eduardo Guimarãe
World Journal of Gastrointestinal Endoscopy.2018; 10(12): 422. CrossRef - Low Volume Polyethylene Glycol (PEG) Plus Ascorbic Acid, a Valid Alternative to Standard PEG
Su Hwan Kim, Ji Won Kim
Gut and Liver.2016; 10(2): 160. CrossRef - Patient Descriptions of Rectal Effluents May Help to Predict the Quality of Bowel Preparation With Photographic Examples
Hoonsub So, Sun-Jin Boo, Hyungil Seo, Ho-Su Lee, Hyojeong Lee, Sang Hyoung Park, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Jin-Ho Kim, Seungbong Han, Dong-Hoon Yang
Intestinal Research.2015; 13(2): 153. CrossRef - Randomized controlled trial of low-volume bowel preparation agents for colonic bowel preparation: 2-L polyethylene glycol with ascorbic acid versus sodium picosulfate with magnesium citrate
Seong Ran Jeon, Hyun Gun Kim, Ji Seong Lee, Jin-Oh Kim, Tae Hee Lee, Jun-Hyung Cho, Yong Hun Kim, Joo Young Cho, Joon Seong Lee
International Journal of Colorectal Disease.2015; 30(2): 251. CrossRef - Colon Transit Time May Predict Inadequate Bowel Preparation in Patients With Chronic Constipation
Hong Jun Park, Myeong Hun Chae, Hyun-Soo Kim, Jae Woo Kim, Moon Young Kim, Soon Koo Baik, Sang Ok Kwon, Hee Man Kim, Kyong Joo Lee
Intestinal Research.2015; 13(4): 339. CrossRef - Bowel Preparation, the First Step for a Good Quality Colonoscopy
Ho-Su Lee, Jeong-Sik Byeon
Intestinal Research.2014; 12(1): 1. CrossRef
- Efficacy and safety of same‐day preparation with sodium picosulfate plus magnesium citrate on the day of colonoscopy for bowel preparation: Multicenter, single‐arm, open‐label study
- 5,803 View
- 54 Download
- 16 Web of Science
- 19 Crossref
Case Report
- Ulcerative Colitis Complicating Pseudomembranous Colitis of the Right Colon
- Hee Rin Joo, Tae Oh Kim, Tae Gyoon Kim, Eun Hee Seo, Jongha Park, Seung Ha Park, Sung Yeon Yang, Young Soo Moon
- Intest Res 2011;9(2):144-147. Published online August 30, 2011
- DOI: https://doi.org/10.5217/ir.2011.9.2.144
-
Abstract
PDF
- Clostridium difficile (C. difficile) is a cytotoxin-producing anaerobic gram-positive rod that is responsible for pseudomembranous colitis (PMC). The incidence of C. difficile is increasing in ulcerative colitis (UC) and inflammatory bowel disease patients and is associated with a more severe course, a longer hospital stay, higher financial costs, a greater likelihood of colectomy, and high mortality. PMC may occur anywhere along the intestinal tract, but it is often found in the distal colon. PMC involving the proximal colon with rectosigmoid sparing is rarely reported in patients with UC. We describe the case of a 35-year-old woman in remission from UC who presented with frequent diarrhea and abdominal pain. She was treated with ciprofloxacin for infectious enterocolitis at a local hospital; however, her symptoms did not improve. A colonoscopy revealed yellow-white plaques with edematous, erythematous from the proximal ascending colon to the cecum, and feces positive for C. difficile toxin. She was treated with metronidazole (500 mg, three times a day) for two weeks, and improved rapidly. Physicians should carefully examine the entire colon via colonoscopy, and perform stool exams for C. difficile in patients with UC who have been treated with antibiotics and in those who develop prolonged diarrhea despite medical treatment. (Intest Res 2011;9:144-147)
- 2,825 View
- 20 Download
Original Article
- Clinical and Endoscopic Characteristics of Acute Hemorrhagic Rectal Ulcer and the Risk Factor of Rebleeding
- Sung Han Park, Tae Oh Kim, Jung Nam Lee, Hyun Seok You, Dong Yup Ryu, Bong Yun Lee, Geun Am Song
- Intest Res 2009;7(1):8-13. Published online June 30, 2009
-
Abstract
PDF
- Background/Aims
Acute hemorrhagic rectal ulcers (AHRUs) are rare and have not been thoroughly studied. This study aimed to assess the clinical and endoscopic characteristics of AHRUs and to determine the risk factors for rebleeding after the initial management. Methods: Thirty patients who underwent colonoscopy within 48 hours of the onset of hematochezia were consecutively enrolled between January 2004 and December 2007. The patients were divided into a rebleeding group and a non-rebleeding group according to presence of recurrent bleeding after initial management. We analyzed the clinical features, including the underlying disorder, the Karnofsky performance status (PS), the use of anticoagulant or antiplatelet agents, the endoscopic findings, and the methods used for hemostasis. Results: All of the patients were elderly, in a bedridden status, and all had experienced the sudden onset of massive, fresh rectal bleeding without pain. The characteristics of the lesions on colonoscopy included solitary or multiple rectal ulcers, or Dieulafoy lesions located in the distal rectum. There were no differences between the two groups based on mean age, gender, use of anticoagulant or antiplatelet agents, PS, methods of hemostasis, and clinical outcomes. The PT (INR) and endoscopic findings (Dieulafoy types), however, differed significantly between the two groups (p=0.024 and p=0.013, respectively). Conclusions: When massive hematochezia occurs in bedridden patients with severe comorbid illnesses, AHRUs should be considered in the differential diagnosis. It is advisable to be vigilant for rebleeding in patients with prolongation of the PT (INR) and Dieulafoy-type ulcers on colonoscopy.
- 1,810 View
- 22 Download
Selected Summary
- Erythrocyte-Mediated Delivery of Dexamethasone in Patients with Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study (American Journal of Gastroenterology 2008;103:2509-2516)
- Tae Oh Kim
- Intest Res 2008;6(2):154-156. Published online December 30, 2008
- 1,525 View
- 16 Download
Case Report
- A Case of Acute Lower Gastrointestinal Bleeding from Appendix
- Sun Mi Lee, Tae Oh Kim, Gwang Ha Kim, Jung Heo, Dae Hwan Kang, Geun Am Song, Mong Cho
- Intest Res 2007;5(2):184-187. Published online December 30, 2007
-
Abstract
PDF
- It is known that the most common causes of lower gastrointestinal bleeding are diverticulosis and angiodysplasia. In addition to these causes, a malignant neoplasm, hemorrhoids, Meckel’s diverticulum, infection, Crohn’s disease, inflammatory disease due to radiation treatment, ischemic colitis, and vasculitis due to connective tissue disease can commonly produce lower gastrointestinal bleeding. A colon varix, endometriosis, or Dieulafoy's lesion rarely causes lower gastrointestinal bleeding. Lower gastrointestinal bleeding that is localized to the appendix is extremely rare, and may be caused by angiodysplasia, an ulcer due to aspirin, endometriosis, a lymphoma, or fissures on the mucous membrane associated with appendicitis. A colonoscopy, radioisotope scan, and angiography are modalities used to diagnose lower gastrointestinal bleeding, and recently, multi-detector row CT (MDCT) has been used for cases where it has been difficult to locate a lesion with other methods or to diagnose a patient when endoscopic access was not available. We report a case of a patient that came to the hospital complaining of hematochezia, and bleeding in the appendix was determined after an MDCT examination and colonoscopy. Subsequently, the patient was treated with surgery. (Intest Res 2007;5:184-187)
- 1,505 View
- 21 Download
Original Article
- Clinicopathologic Features and Endoscopic Treatment of Laterally Spreading Tumors of the Colorectum
- Cheol Woong Choi, Sun Mi Lee, Tae Oh Kim, Gwang Ha Kim, Jung Heo, Dae Hwan Kang, Geun Am Song, Mong Cho
- Intest Res 2007;5(1):33-37. Published online June 30, 2007
-
Abstract
PDF
- Background/Aims
Laterally spreading tumors (LSTs) of the colorectum are defined as lesions greater than 10 mm in diameter with a low vertical axis that extend laterally along the luminal wall. We analyzed the clinicopathologic characteristics and endoscopic treatment of LSTs on the colorectum. Methods: The 127 colorectal LSTs were collected from January 2005 through February 2007. Those lesions were analysed according to their endoscopic and pathologic findings. Results: 67 LSTs (52.8%) were more than 20 mm in size. Most common involved sites of LSTs were rectum (32.4%) and ascending colon (25.9%). Most common subtype of LSTs were granular-homogeneous type (G-H) (37%). Histologic types were 76 tubular adenomas (59.8%), 24 tubulovillous adenomas (18.8%), 6 villous adenomas (4.8%) and 21 adenocarcinoma (16.6%). Both nodular mixed type (G-NM) and pseudo-depressed type (NG-PD) contained a carcinomatous component with high frequency as compared with the G-H type. Carcinoma invaded into the submucosa were present in 3 lesions of G-NM type and 6 lesions of NG-PD type. Conclusions: LSTs showed different clinicopathologic characteristics depending on the morphologic classification. G-NM type or NG-PD type had more malignant potential than other types. Endoscopists should select an adequate therapeutic strategy for large LST with careful consideration. (Intest Res 2007;5:33-37)
- 1,461 View
- 15 Download
First
Prev
